Evidence map›Paper›PMID 19536326›Full record

ArticlePLoS medicine2009

DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.

Steven T Lott, Nanyue Chen, Dawn S Chandler, Qifeng Yang, Luo Wang, Marivonne Rodriguez, Hongyan Xie, Seetharaman Balasenthil, Thomas A Buchholz, Aysegul A Sahin and 15 more

Open access · goldAbstract read
In one paragraph

Article in PLoS medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Association ofBreast cancer : basic and clinical research · 2020
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Dysregulation of ubiquitin ligases in cancer.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2015
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 2 countries.

Steven T LottDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Nanyue Chen
Dawn S Chandler
Qifeng Yang
Luo Wang
Marivonne Rodriguez
Hongyan Xie
Seetharaman Balasenthil
Thomas A Buchholz
Aysegul A Sahin
Katrina Chaung
Baili Zhang
Shodimu-Emmanu Olufemi
Jinyun Chen
Henry Adams
Vimla Band
Adel K El-Naggar
Marsha L Frazier
Khandan Keyomarsi
Kelly K Hunt
Subrata Sen
Bruce Haffty
Stephen M Hewitt
Ralf Krahe
Ann McNeill Killary
The University of Texas MD Anderson Cancer Center · USJohnson University · USCenter for Cancer Research · USCenter for Translational Molecular Medicine · NLRadiation Oncology Associates · USSociety of Surgical Oncology · USUniversity of Nebraska Medical Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Tissue Array Research ProgramZICBC010923 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HEWITT, STEPHEN · 2009 to 2014
$4.7M
TRAINING PROGRAM IN MOLECULAR GENETICS OF CANCERT32CA009299 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOZANO, GUILLERMINA · 1985 to 2014
$4.7M
A Novel RING Finger Protein Implicated in NeoplasiaF32CA090036 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI CHANDLER, DAWN S · 2002 to 2003
$87k
NCI NIH HHS CA-16672NCI NIH HHS F32 CA090036NCI NIH HHS P30 CA016672NCI NIH HHS T32 CA009299NCI NIH HHS T32CA09299
6 · The paper itself

Abstract

backgroundBreast cancer in young women tends to have a natural history of aggressive disease for which rates of recurrence are higher than in breast cancers detected later in life. Little is known about the genetic pathways that underlie early-onset breast cancer. Here we report the discovery of DEAR1 (ductal epithelium-associated RING Chromosome 1), a novel gene encoding a member of the TRIM (tripartite motif) subfamily of RING finger proteins, and provide evidence for its role as a dominant regulator of acinar morphogenesis in the mammary gland and as an independent predictor of local recurrence-free survival in early-onset breast cancer. METHODS AND

findingsSuppression subtractive hybridization identified DEAR1 as a novel gene mapping to a region of high-frequency loss of heterozygosity (LOH) in a number of histologically diverse human cancers within Chromosome 1p35.1. In the breast epithelium, DEAR1 expression is limited to the ductal and glandular epithelium and is down-regulated in transition to ductal carcinoma in situ (DCIS), an early histologic stage in breast tumorigenesis. DEAR1 missense mutations and homozygous deletion (HD) were discovered in breast cancer cell lines and tumor samples. Introduction of the DEAR1 wild type and not the missense mutant alleles to complement a mutation in a breast cancer cell line, derived from a 36-year-old female with invasive breast cancer, initiated acinar morphogenesis in three-dimensional (3D) basement membrane culture and restored tissue architecture reminiscent of normal acinar structures in the mammary gland in vivo. Stable knockdown of DEAR1 in immortalized human mammary epithelial cells (HMECs) recapitulated the growth in 3D culture of breast cancer cell lines containing mutated DEAR1, in that shDEAR1 clones demonstrated disruption of tissue architecture, loss of apical basal polarity, diffuse apoptosis, and failure of lumen formation. Furthermore, immunohistochemical staining of a tissue microarray from a cohort of 123 young female breast cancer patients with a 20-year follow-up indicated that in early-onset breast cancer, DEAR1 expression serves as an independent predictor of local recurrence-free survival and correlates significantly with strong family history of breast cancer and the triple-negative phenotype (ER(-), PR(-), HER-2(-)) of breast cancers with poor prognosis.

conclusionsOur data provide compelling evidence for the genetic alteration and loss of expression of DEAR1 in breast cancer, for the functional role of DEAR1 in the dominant regulation of acinar morphogenesis in 3D culture, and for the potential utility of an immunohistochemical assay for DEAR1 expression as an independent prognostic marker for stratification of early-onset disease.

Indexed as

Biomarkers, TumorBreastBreast NeoplasmsCell Line, TumorDisease-Free SurvivalDown-RegulationEpithelial CellsFemaleGene Knockdown TechniquesHumansMorphogenesisMutationNeoplasm Recurrence, LocalPrognosisTripartite Motif ProteinsTumor Suppressor ProteinsBiomarkers, TumorTRIM62 protein, humanTripartite Motif ProteinsTumor Suppressor ProteinsUbiquitin-Protein Ligases

Identifiers

PMID19536326
PMCPMC2673042
OpenAlexW2079020397

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.